Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Morphotek in oncology research deal with U Penn
January 2009
SHARING OPTIONS:

EXTON, Pa.Morphotek Inc. announced recently it signed a sponsored research agreement with The University of Pennsylvania to fund research for the development of therapeutic antibody candidates targeting an antigen associated with hypoxic regions in tumors. Hypoxia is a condition in which suboptimal oxygen concentrations exist in tissues.

"This collaboration builds upon our existing relationships with leading researchers at the University of Pennsylvania for possible advancement of therapeutic monoclonal antibody candidates into clinical trials. Dr. Wafik El-Deiry and his team bring significant expertise to our program in the area of tumor hypoxia, and we are very excited to be working together with his group," says Nicholas C. Nicolaides, president and CEO of Morphotek. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.